1[1]Global surveillance and control of hepatitis C.Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board,Antwerp,Belgium.J Viral Hepat 1999;6:35-47
2[2]Alter MJ,Kruszon-Moran D,Nainan OV,McQuillan GM,Gao F,Moyer LA,Kaslow RA,Margolis HS.The prevalence of hepatitis C virus infection in the United States,1988 through 1994.N Engl J Med 1999;341:556-562
3[3]Hoofnagle JH,Mullen KD,Jones DB,Rustgi V,Di Bisceglie A,Peters M,Waggoner JG,Park Y,Jones EA.Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon.A preliminary report.N Engl J Med 1986;315:1575-1578
4[4]Carithers RL Jr,Emerson SS.Therapy of hepatitis C:meta-analysis of interferon alfa-2b trials.Hepatology 1997;26:83S-88S
5[5]McHutchison JG,Gordon SC,Schiff ER,Shiffman ML,Lee WM,Rustgi VK,Goodman ZD,Ling MH,Cort S,Albrecht JK.Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C.Hepatitis Interventional Therapy Group.N Engl J Med 1998;339:1485-1492
6[6]Poynard T,Marcellin P,Lee SS,Niederau C,Minuk GS,Ideo G,Bain V,Heathcote J,Zeuzem S,Trepo C,Albrecht J.Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus.International Hepatitis Interventional Therapy Group (IHIT).Lancet 1998;352:1426-1432
7[7]Manns MP,McHutchison JG,Gordon SC,Rustgi VK,Shiffman M,Reindollar R,Goodman ZD,Koury K,Ling M,Albrecht JK.Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C:a randomised trial.Lancet 2001;358:958-965
8[8]Fried MW,Shiffman ML,Reddy KR,Smith C,Marinos G,Goncales FL Jr,Haussinger D,Diago M,Carosi G,Dhumeaux D,Craxi A,Lin A,Hoffman J,Yu J.Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.N Engl J Med 2002;347:975-982
9[9]Hadziyannis SJ,Sette H Jr,Morgan TR,Balan V,Diago M,Marcellin P,Ramadori G,Bodenheimer H Jr,Bernstein D,Rizzetto M,Zeuzem S,Pockros PJ,Lin A,Ackrill AM.Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C:a randomized study of treatment duration and ribavirin dose.Ann Intern Med 2004;140:346-355
10[10]Dienstag JL,McHutchison JG.American Gastroenterological Association medical position statement on the management of hepatitis C.Gastroenterology 2006;130:225-230
